摘要
目的探究糖类抗原125(CA125)、人附睾丸蛋白4(HE4)、卵巢癌风险预测模型(ROMA)值联合检测对早期卵巢癌风险的预测价值。方法以50例早期卵巢癌患者为试验组A,50例卵巢良性肿瘤患者为试验组B,50例健康体检者为对照组,均接受CA125、HE4水平检测,计算ROMA值,并分析CA125、HE4、ROMA值单独、联合诊断卵巢癌的价值。结果试验组A的CA125、HE4水平、ROMA值高于试验组B和对照组(P<0.05);试验组B的CA125、HE4水平、ROMA值高于对照组(P<0.05)。CA125+HE4+ROMA联合诊断卵巢癌的灵敏度、准确度、阴性预测值均高于单独CA125、单独HE4、单独ROMA值的诊断结果(P<0.05)。结论CA125、HE4、ROMA值联合检测早期乳腺癌,可为患者疾病的确诊以及治疗方案的制定提供参考依据。
Objective To explore the predictive value of combined detection of carbohydrate antigen 125(CA125),human epstein 4(HE4)and ovarian cancer risk prediction model(ROMA)value for the risk of early ovarian cancer.Methods Fifty patients with early ovarian cancer were taken as experimental group A,50 patients with benign ovarian tumor were taken as experimental group B,and 50 objects with healthy physical examination were taken as control group.All of them underwent CA125 and HE4 levels detection,and ROMA value was calculated.CA125,HE4 and ROMA value in the diagnosis of ovarian cancer alone or in combination were analyzed.Results The levels of CA125,HE4 and ROMA value in the experimental group A were higher than those in the experimental group B and the control group(P<0.05);the levels of CA125,HE4 and ROMA value in the experimental group B were higher than those in the control group(P<0.05).The sensitivity,accuracy and negative predictive value of CA125+HE4+ROMA value in the diagnosis of ovarian cancer were higher than those of CA125 alone,HE4 alone and ROMA value alone(P<0.05).Conclusion The combined detection of CA125,HE4 and ROMA value can provide reference for the diagnosis and treatment of early breast cancer.
作者
舒琪
王丽萍
岳丽娟
SHU Qi;WANG Liping;YUE Lijuan(No.215 Hospital of Shaanxi Nuclear Industry,Xianyang 712000;the Hospital of Luochuan County,Yan'an 727400;Hanzhong Central Hospital,Hanzhong 723000,China)
出处
《临床医学研究与实践》
2020年第32期26-28,共3页
Clinical Research and Practice
基金
陕西省重点研发计划项目(No.2017SF-074)。